Anuh Pharma Limited has received World Health Organization (WHO) Prequalification approval for its Active Pharmaceutical Ingredient (API), Amodiaquine Hydrochloride USP. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to stock exchanges on 04 May 2026. This regulatory milestone reinforces the company's standing as a credible supplier for international anti-malarial programmes.

WHO Prequalification: A Key Regulatory Milestone

The WHO Prequalification programme is an internationally recognised certification that enables pharmaceutical manufacturers to demonstrate compliance with rigorous global quality, safety, and efficacy standards. Approval under this programme is particularly significant for APIs intended for use in public health programmes and procurement by international health agencies. The following table summarises the key details of the approved product:

About Amodiaquine Hydrochloride USP

Amodiaquine Hydrochloride is an essential medicine listed by the WHO and is widely used in combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria. As an API, it forms the active core of finished anti-malarial formulations deployed across global health programmes. The WHO Prequalification of this product by Anuh Pharma validates the company's manufacturing capabilities against stringent international benchmarks and positions it as a preferred API supplier for global anti-malarial programmes, including those funded by donor agencies.

ANUH PHARMA LTD has issued a public notice to shareholders regarding the opening of a special window for transfer and dematerialisation of physical shares. The announcement, published on April 17, 2026, in Financial Express (English) and Mumbai Lakshdeep (Marathi) editions, follows the SEBI Circular dated January 30, 2026.

Special Window Details

The special window facility addresses physical share transfer requests that were lodged prior to April 01, 2019, but remained unprocessed due to various deficiencies. According to the company's notice, this window is specifically available for requests that were rejected, returned, or not attended due to deficiencies in documents, process, or other reasons.

Eligibility Criteria

The company has provided a clear matrix to help investors understand their eligibility for the special window:

Eligible Cases:

• Fresh lodgement (not lodged before April 01, 2019) with original share certificates
• Previously lodged but rejected/returned requests with original certificates

Ineligible Cases:

• Previously lodged requests where original certificates are no longer with the investor
• Cases where shares were not lodged and original certificates are not available

Process and Requirements

Investors wishing to utilise this facility must contact the company's Registrar and Share Transfer Agent, Bigshare Services Private Limited. The registrar is located at Office No S6-2, 6th Floor, Pinnacle Business Park, Mahakali Caves Road, Andheri (East), Mumbai - 400093.

The notice emphasises that only requests accompanied by original share certificates along with transfer deeds and other supporting documents will be considered under the special window. This disclosure has been simultaneously uploaded on the company's website at www.anuhpharma.com for broader accessibility.

Regulatory Compliance

The initiative demonstrates ANUH PHARMA's commitment to regulatory compliance and shareholder service. The special window provides a valuable opportunity for eligible shareholders to complete their pending transfer and dematerialisation processes, ensuring their holdings are properly recorded in dematerialised form as per current market practices.